- Home
- TSHA vs BCX Comparison
TSHA vs BCX Comparison
Compare TSHA & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- BCX
- Stock Information
- Founded
- TSHA 2019
- BCX 2011
- Country
- TSHA United States
- BCX United States
- Employees
- TSHA N/A
- BCX N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- TSHA Health Care
- BCX Finance
- Exchange
- TSHA Nasdaq
- BCX Nasdaq
- Market Cap
- TSHA 728.4M
- BCX 747.5M
- IPO Year
- TSHA 2020
- BCX N/A
- Fundamental
- Price
- TSHA $2.94
- BCX $9.58
- Analyst Decision
- TSHA Strong Buy
- BCX
- Analyst Count
- TSHA 7
- BCX 0
- Target Price
- TSHA $8.71
- BCX N/A
- AVG Volume (30 Days)
- TSHA 2.7M
- BCX 370.6K
- Earning Date
- TSHA 08-12-2025
- BCX 01-01-0001
- Dividend Yield
- TSHA N/A
- BCX 6.99%
- EPS Growth
- TSHA N/A
- BCX N/A
- EPS
- TSHA N/A
- BCX N/A
- Revenue
- TSHA $8,098,000.00
- BCX N/A
- Revenue This Year
- TSHA N/A
- BCX N/A
- Revenue Next Year
- TSHA N/A
- BCX N/A
- P/E Ratio
- TSHA N/A
- BCX N/A
- Revenue Growth
- TSHA N/A
- BCX N/A
- 52 Week Low
- TSHA $1.05
- BCX $8.25
- 52 Week High
- TSHA $3.31
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- TSHA 62.34
- BCX 48.66
- Support Level
- TSHA $2.69
- BCX $9.54
- Resistance Level
- TSHA $3.12
- BCX $9.74
- Average True Range (ATR)
- TSHA 0.17
- BCX 0.11
- MACD
- TSHA 0.02
- BCX -0.00
- Stochastic Oscillator
- TSHA 68.97
- BCX 51.43
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.